A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon (EXPANSE-PTCA)

  • days left to enroll
  • participants needed
  • sponsor
Updated on 19 June 2022


The objective of this study is to evaluate safety and effectiveness of the Lacrosse NSE ALPHA coronary dilatation catheter during PCI in subjects with stenotic coronary arteries.


The investigation is a prospective, multi-center, single arm clinical study. The study will be conducted in up to 15 investigational sites in the U.S. This study will enroll and treat 200 subjects, including a minimum of 30 subjects with in-stent restenosis (ISR).

The population for this study is subjects with stenotic coronary artery disease who are suitable candidates for PTCA.

After screening for initial inclusion and exclusion criteria, eligible subjects will be asked to participate in the study by signing a consent form. Following consent, subjects will undergo a baseline visit where additional eligibility criteria will be assessed. An angiogram will be completed to assess for angiographic eligibility. If a non-target lesion is identified, it must be treated successfully prior to target lesion treatment. Once treatment of the target lesion(s) has been attempted, the subject will be considered enrolled in the study.

Subjects will be followed through hospital discharge.

Condition Coronary Stenosis, Coronary Artery Stenosis, In-stent Restenosis
Treatment Lacrosse NSE ALPHA coronary dilatation catheter
Clinical Study IdentifierNCT04985773
Last Modified on19 June 2022


Yes No Not Sure

Inclusion Criteria

Age 18 years or older
Willing to provide written informed consent and written HIPAA authorization prior to initiation of study-related procedures
Agree to not participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study
Clinical evidence of ischemic heart disease, stable/unstable angina, or silent ischemia
Acceptable candidate for PCI and emergency coronary artery bypass grafting and is planned for possible PTCA and/or stent placement
Angiographic inclusion criteria
De novo or restenotic lesion(s) in native coronary arteries, including in-stent restenosis
A maximum of two lesions, including at least one target lesion, in single or double vessel coronary artery disease
If two target lesions are defined, then no non-target lesions can be treated
If a single target lesion is defined, then a single non-target lesion may be treated, but if so, it must be located in a different coronary artery from the target lesion
Target lesion(s) must have a reference vessel diameter between 2.0 mm and 4.0 mm by
visual estimation
Target lesion(s) must have a diameter stenosis of (a) ≥70% by visual estimation or (b) >50% by visual estimation and a fractional flow reserve (FFR) of <0.80 or resting full-cycle ratio (RFR) or instantaneous wave-free ratio (iFR) <0.9
Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion; must not, in the opinion of the investigator, impact the conduct or completion of the index procedure; and must be deemed a clinical angiographic success as visually assessed by the investigator

Exclusion Criteria

Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, a clopidogrel non-responder, or sensitivity to contrast media that cannot be adequately pre-medicated or replaced with a clinically suitable alternative
Known diagnosis of type I myocardial infarction (resulting from primary reduction of flow from a culprit lesion likely to have a thrombotic component) within 7 days prior to the index procedure
Known pregnancy or is nursing. Women of child-bearing potential should have a documented negative pregnancy test within 7 days prior to index procedure
Planned target lesion treatment with atherectomy (rotational, orbital or laser), cutting balloon, thrombectomy, lithotripsy or an unapproved device during the index procedure
Serum creatinine >2.0 mg/dl within 7 days prior to the index procedure
Cerebrovascular accident within 6 months prior to the index procedure
Active peptic ulcer or active gastrointestinal bleeding within 6 months prior to the index procedure
Left ventricular ejection fraction <30% based on most recent measurement within a year of the index procedure (if LVEF is not available in the medical records, it may be obtained at the time of the index procedure, prior to enrollment)
Target lesion located within a bypass graft (venous or arterial) or graft anastomosis
Previous percutaneous intervention, within 9 months before the study procedure, on lesions in a target vessel (including side branches) that are located within 10 mm from the current target lesion(s)
Target lesion(s) with complete total occlusion defined as the complete obstruction of a native coronary artery, exhibiting TIMI 0 or TIMI 1 flow, with an occlusion duration of at least 3 months
Unstable hemodynamics or shock
Other medical condition which might, in the opinion of the investigator, put the patient at risk or confound the results of the study
Angiographic exclusion criteria
Target lesion(s) longer than 32 mm by visual estimation
Extreme angulation (90º or greater) within 5 mm of the target lesion
Target lesion(s) demonstrating flow limiting dissection (NHLBI Grade C or higher) prior to deployment of the Lacrosse NSE ALPHA
Unprotected left main coronary artery disease (>50% diameter stenosis)
Coronary artery spasm of the target vessel in the absence of a significant stenosis
Target lesion(s) with angiographic presence of probable or definite thrombus
Target lesion(s) involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter
Target lesion(s) located in bifurcation beyond stent struts
Target lesion(s) located distal to an implanted stent
Target lesion(s) with stent damage
Non-target lesion that meets any of the following criteria
Located within a bypass graft (venous or arterial)
Located in an unprotected left main coronary artery
Involves a bifurcation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note